Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva

JERUSALEM & SAN DIEGO--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (“Teva”), a world leading global pharmaceutical company, and Ignyta, Inc. (Nasdaq: RXDX) (“Ignyta”), a precision oncology biotechnology company, today announced the acquisition by Ignyta of the worldwide rights and assets relating to four targeted oncology development programs in exchange for 1.5 million shares (6%) of Ignyta’s common stock. Concurrently, Ignyta has entered into stock purchase agreements wi

For more information, please visit
http://www.businesswire.com/news/home/20[...]isition-Ignyta-Oncology-Assets

You need to login to post comments.

Feed last updated 2017/07/31 @1:07 AM

0 COMMENTS:

VOCAPIA and SYSTRAN demonstrate an automated speech translation solution at EUROSATORY 2016 - GlobeNewswire (press release) views: 1543

Instagram is adding automatic in-app text translation - The Verge views: 1530

Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1528

F.A.Q. | Terms and conditions